Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USPlabs Crafts DMAA Defense As Shield Against Further Damage

This article was originally published in The Tan Sheet

Executive Summary

USPlabs’ compliance with FDA’s request to cease marketing DMAA-containing products came following lengthy and detailed responses to the agency that could shield the firm from class action lawsuits and state investigations.


Related Content

Five Shanghai Suspects Charged After FDA Undercover Work On Spiked Supplements
Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements
USPlabs' DMAA Supplement Source Convicted In Separate Criminal Case
FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts